UCL logo

UCL Discovery

UCL home » Library Services » Electronic resources » UCL Discovery

Browse by UCL Departments and Centres

Up a level
Export as [feed] RSS 2.0 [feed] RSS 1.0 [feed] Atom
Group by: Author | Type
Jump to: A | B | C | D | E | F | G | H | K | L | M | O | P | Q | R | S | T | U | V | W | Y
Number of items: 133.

A

André, T; Boni, C; Navarro, M; Tabernero, J; Hickish, T; Topham, C; ... de Gramont, A; + view all (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol , 27 (19) 3109 - 3116. 10.1200/JCO.2008.20.6771.

Arkenau,; (2009) Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: A pooled analysis of randomized trials (Journal of Clinical Oncology (2008) 26 (5910-5917)). Journal of Clinical Oncology , 27 (34) 5859 - 5859.

Arkenau, H; Evans, J; Lokelma, M; Roxburgh, P; Morisson, R; Coffey, M; ... de Bono, J; + view all (2009) A phase I study of the combination of intravenous Reolysin (REO) and gemcitabine (GEM) in patients (pts) with advanced cancer. In: JOURNAL OF CLINICAL ONCOLOGY. (pp. ? - ?). AMER SOC CLINICAL ONCOLOGY

Arkenau, H-T; (2009) Capecitabine/oxaliplatin results in outcome similar to infusional 5 FU/leucovorin/oxaliplatin in MCRC: Results of a meta-analysis. American Journal of Hematology/ Oncology , 8 (5)

Arkenau, HT; (2009) Gastric cancer in the era of molecularly targeted agents: current drug development strategies. J Cancer Res Clin Oncol , 135 (7) 855 - 866. 10.1007/s00432-009-0583-7.

Arkenau, HT; Brunetto, AT; Barriuso, J; Olmos, D; Eaton, D; de Bono, J; ... Kaye, S; + view all (2009) Clinical benefit of new targeted agents in phase I trials in patients with advanced colorectal cancer. Oncology , 76 (3) 151 - 156. 10.1159/000195884.

B

Bajwa, A; Blunt, N; Vyas, S; Suliman, I; Bridgewater, J; Hochhauser, D; ... O'Bichere, A; + view all (2009) Primary tumour resection and survival in the palliative management of metastatic colorectal cancer. EJSO , 35 (2) 164 - 167. 10.1016/j.ejso.2008.06.005.

BBC, NO; (2009) Thalidomide lung cancer 'failure'. UNSPECIFIED

Berenjeno, IM; Vanhaesebroeck, B; (2009) PI3K regulatory subunits lose control in cancer. Cancer Cell , 16 (6) 449 - 450. 10.1016/j.ccr.2009.11.017.

Bhosle, J; Makris, A; Hartley, JA; Hochhauser, D; (2009) Effect of chronic exposure to tyrosine kinase inhibitors on chemotherapy-induced DNA damage in the SKBR3 breast cancer cell line. In: CANCER RESEARCH. (pp. 117S - 117S). AMER ASSOC CANCER RESEARCH

Billottet, C; Banerjee, L; Vanhaesebroeck, B; Khwaja, A; (2009) Inhibition of Class I Phosphoinositide 3-Kinase Activity Impairs Proliferation and Triggers Apoptosis in Acute Promyelocytic Leukemia without Affecting Atra-Induced Differentiation. CANCER RES , 69 (3) 1027 - 1036. 10.1158/0008-5472.CAN-08-2608.

Black, E; Glasspool, DW; Grando, MA; Patkar, V; Fox, J; (2009) Goal-Based Decisions for Dynamic Planning. In: Combi, C and Shahar, Y and AbuHanna, A, (eds.) ARTIFICIAL INTELLIGENCE IN MEDICINE, PROCEEDINGS. (pp. 96 - 100). SPRINGER-VERLAG BERLIN

Boone, JJM; Bhosle, J; Tilby, MJ; Hartley, JA; Hochhauser, D; (2009) Involvement of the HER2 pathway in repair of DNA damage produced by chemotherapeutic agents. MOL CANCER THER , 8 (11) 3015 - 3023. 10.1158/1535-7163.MCT-09-0219.

Brown, ACN; Hallouane, D; Mawby, WJ; Karet, FE; Saleem, MA; Howie, AJ; Toye, AM; (2009) RhCG is the major putative ammonia transporter expressed in the human kidney, and RhBG is not expressed at detectable levels. AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY , 296 (6) F1279 - F1290. 10.1152/ajprenal.00013.2009.

C

Carle, D; Bielack, S; Sydes, M; Butterfass-Bahloul, T; Calaminus, G; Jovic, G; ... Bernstein, M; + view all (2009) The European and American Osteosarcoma Study Group protocol EURAMOS 1: Successful transatlantic cooperation in osteosarcoma. In: Connective Tissue Oncology Society, Miami,.

Cave, J; Edwards, SG; Miller, RF; Ardeshna, KM; Lee, SM; (2009) Should we implement 'opt-out' HIV testing for patients with lymphoma? CLIN MED , 9 (4) 320 - 322.

Chew, SK; Chen, P; Link, N; Galindo, KA; Pogue, K; Abrams, JM; (2009) Genome-wide silencing in Drosophila captures conserved apoptotic effectors. Nature , 460 (7251) 123 - 127. 10.1038/nature08087.

Constantinou, A; Epenetos, AA; Hreczuk-Hirst, D; Jain, S; Wright, M; Chester, KA; Deonarain, MP; (2009) Site-Specific Polysialylation of an Antitumor Single-Chain Fv Fragment. BIOCONJUGATE CHEM , 20 (5) 924 - 931. 10.1021/bc8005122.

Croucher, C; Whelan, JS; Møller, H; Davies, EA; (2009) Trends in the incidence and survival of cancer in teenagers and young adults: Regional analysis for South East England 1960 - 2002. Clinical Oncology , 21 417 - 424.

Cunningham, D; Sirohi, B; Pluzanska, A; Utracka-Hutka, B; Zaluski, J; Glynne-Jones, R; ... Cassidy, J; + view all (2009) Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol , 20 (2) 244 - 250. 10.1093/annonc/mdn638.

D

Dancey, G; Begent, RH; Meyer, T; (2009) Imaging in targeted delivery of therapy to cancer. TARGET ONCOL , 4 (3) 201 - 217. 10.1007/s11523-009-0119-8.

Dancey, G; Violet, J; Malaroda, A; Green, AJ; Sharma, SK; Francis, R; ... McNamara, C; + view all (2009) A Phase I Clinical Trial of CHT-25 a I-131-Labeled Chimeric Anti-CD25 Antibody Showing Efficacy in Patients with Refractory Lymphoma. CLIN CANCER RES , 15 (24) 7701 - 7710. 10.1158/1078-0432.CCR-09-1421.

Davis, R; Sielaff, A; Ruprich, J; Westrate, L; Tronrud, C; Ferguson, A; ... Lee, M; + view all (2009) Design, synthesis, biophysical and biological studies of fluorescent Hoechst-polyamide hybrid molecules. ABSTR PAP AM CHEM S , 237 ? - ?.

Dearling, JLJ; Flynn, AA; Qureshi, U; Whiting, S; Boxer, GM; Green, A; ... Pedley, RB; + view all (2009) Localization of radiolabeled anti-CEA antibody in subcutaneous and intrahepatic colorectal xenografts: influence of tumor size and location within host organ on antibody uptake. NUCL MED BIOL , 36 (8) 883 - 894. 10.1016/j.nucmedbio.2009.07.003.

Desai, K; Bhattacharya, S; Srirajaskanthan, R; Morgan-Rowe, L; Toumpanakis, C; Meyer, T; Caplin, M; (2009) Analysis of association between carcinoid heart disease and mesenteric fibrosis in patients with midgut carcinoid tumour. In: JOURNAL OF CLINICAL ONCOLOGY.

Durand, CA; Hartvigsen, K; Fogelstrand, L; Kim, S; Iritani, S; Vanhaesebroeck, B; ... Gold, MR; + view all (2009) Phosphoinositide 3-kinase p110 delta regulates natural antibody production, marginal zone and B-1 B cell function, and autoantibody responses. J Immunol , 183 (9) 5673 - 5684. 10.4049/jimmunol.0900432.

E

Ella, W; Short, SC; (2009) Using retinoids to increase radio-iodine uptake in thyroid cancer: role as potential redifferentiation agents. In: The handbook on iodine. Elsevier

Essafi, A; Gomes, AR; Pomeranz, KM; Zwolinska, AK; Varshochi, R; McGovern, UB; Lam, EW; (2009) Studying the subcellular localization and DNA-binding activity of FoxO transcription factors, downstream effectors of PI3K/Akt. Methods Mol Biol , 462 201 - 211. 10.1007/978-1-60327-115-8_13.

F

Fern, L; Ashton, J; Broonan, K; Irving, C; Millington, H; Starkey, C; ... Whelan, J; + view all (2009) Involving young people with cancer in research. The National Cancer Research Institute’s Teeange and Young Adult Core Consumer Group – a new and evolving model. In: National Cancer Research Institute Cancer Conference, 2009, Birmingham.

Finerty, MJ; Bingham, JP; Hartley, JA; Shipman, M; (2009) Azinomycin bisepoxides containing rigid aromatic linkers: synthesis, cytotoxicity and DNA interstrand cross-linking activity. TETRAHEDRON LETT , 50 (26) 3648 - 3650. 10.1016/j.tetlet.2009.03.123.

Fox, J; Patkar, V; Chronakis, I; Begent, R; (2009) From practice guidelines to clinical decision support: closing the loop. J ROY SOC MED , 102 (11) 464 - 473. 10.1258/jrsm.2009.090010.

Francis, RE; Myatt, SS; Krol, J; Hartman, J; Peck, B; McGovern, UB; ... Lam, EW; + view all (2009) FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol , 35 (1) 57 - 68.

G

George, S; Lal, R; Camidge, DR; Arkenau, H; Chick, J; Poondru, S; ... Scurr, M; + view all (2009) Final results of a dose escalation (DE), pharmacokinetic (PK), and pharmacodynamic (PD) study of two schedules of OSI-930 in patients (pts) with advanced solid tumors. In: JOURNAL OF CLINICAL ONCOLOGY. (pp. ? - ?). AMER SOC CLINICAL ONCOLOGY

Giampieri, S; Manning, C; Hooper, S; Jones, L; Hill, CS; Sahai, E; (2009) Localized and reversible TGF beta signalling switches breast cancer cells from cohesive to single cell motility. NAT CELL BIOL , 11 (11) 1287 - U49. 10.1038/ncb1973.

Gibson, F; Aldiss, S; Taylor, RM; Maguire, R; Kearney, N; (2009) Involving health professionals in the development of an advanced symptom management system for young people: The ASyMS (c)-YG study. EUR J ONCOL NURS , 13 (3) 187 - 192. 10.1016/j.ejon.2009.03.004.

Gibson, F; Pearce, S; Eden, T; Glaser, A; Hooker, L; Whelan, J; Kelly, D; (2009) CANCER IN YOUNG PEOPLE: A NARRATIVE STUDY TO EXPLORE THEIR EXPERIENCE FROM FIRST SYMPTOMS TO THE DIAGNOSIS OF CANCER. In: PEDIATR BLOOD CANCER. (pp. 751 - 751). WILEY-LISS

Gollmer, K; Asperti-Boursin, F; Tanaka, Y; Okkenhaug, K; Vanhaesebroeck, B; Peterson, JR; ... Stein, JV; + view all (2009) CCL21 mediates CD4+ T-cell costimulation via a DOCK2/Rac-dependent pathway. Blood , 114 (3) 580 - 588. 10.1182/blood-2009-01-200923.

H

Haas, TL; Emmerich, CH; Gerlach, B; Schmukle, AC; Cordier, SM; Rieser, E; ... Walczak, H; + view all (2009) Recruitment of the linear ubiquitin chain assembly complex stabilizes the TNF-R1 signaling complex and is required for TNF-mediated gene induction. Mol Cell , 36 831 - 844. 10.1016/j.molcel.2009.10.013.

Hall, JRAS; SC,; (2009) Management of Glioblastoma Multiforme in HIV patients: a case series and review of published studies. Clinical Oncology

Harland, SJ; Welch, R; Huddart, R; Stenning, S; Pollock, P; Gabe, R; (2009) On the necessity for postchemotherapy surgery for residual abdominal masses in metastatic nonseminomatous germ cell tumors (NSGCT) of testis. In: JOURNAL OF CLINICAL ONCOLOGY. (pp. ? - ?). AMER SOC CLINICAL ONCOLOGY

Hatton, C; Peniket, A; Tusold, A; Collins, G; Joyner, M; Lee, R; ... Lee, SM; + view all (2009) Single arm phase II open label study of thalidomide in patients with refractory or relapsed diffuse large B cell lymphoma. In: (Proceedings) 49th Annual Scientific Meeting/British Society for Haematology, Brighton.. (pp. 13 - ?). British Journal of Haematology

Hewish, M; Miller, R; Forster, MD; Smith, IE; (2009) Severe synergistic toxicity from docetaxel in a patient treated concurrently with protease inhibitors as part of HIV-exposure prophylaxis: a case report. Journal of Medical Case Reports , 3 8866 - ?.

Hochhauser, D; Meyer, T; Spanswick, VJ; Wu, J; Clingen, PH; Loadman, P; ... Jodrell, D; + view all (2009) Phase I Study of Sequence-Selective Minor Groove DNA Binding Agent SJG-136 in Patients with Advanced Solid Tumors. CLIN CANCER RES , 15 (6) 2140 - 2147. 10.1158/1078-0432.CCR-08-1315.

Hochhauser, D; Meyer T, L; P, S; V J, C; M, B; R H, W; ... D,; + view all (2009) Phase I study of the DNA minor groove binding pyrrolobenzodiazepine dimer (SJG 136) administered every 21 days in patients with advanced solid tumours. Clinical Cancer Research , 15 (6) 2140 - 2147.

Howard, PW; Chen, Z; Gregson, SJ; Masterson, L; Tiberghien, AC; Cooper, N; ... Thurston, DE; + view all (2009) Synthesis of a novel C2/C2?-aryl-substituted pyrrolo[2,1-c][1,4]benzodiazepine dimer prodrug with improved water solubility and reduced DNA reaction rate. Biorganic and Medicinal Chemistry Letters , 19 (22) 6463 - 6466. 10.1016/j.bmcl.2009.09.012.

K

Kimpfler, S; Sevko, A; Ring, S; Falk, C; Osen, W; Frank, K; ... Umansky, V; + view all (2009) Skin melanoma development in ret transgenic mice despite the depletion of CD25+Foxp3+ regulatory T cells in lymphoid organs. J Immunol , 183 (10) 6330 - 6337. 10.4049/jimmunol.0900609.

Kok, K; Geering, B; Vanhaesebroeck, B; (2009) Regulation of phosphoinositide 3-kinase expression in health and disease. Trends Biochem Sci , 34 (3) 115 - 127. 10.1016/j.tibs.2009.01.003.

Kok, K; Nock, GE; Verrall, EA; Mitchell, MP; Hommes, DW; Peppelenbosch, MP; Vanhaesebroeck, B; (2009) Regulation of p110δ PI 3-Kinase Gene Expression. PLoS One , 4 (4) , Article e5145. 10.1371/journal.pone.0005145. Green and gold open access
file

Kristeleit, R; Calvert, H; Arkenau, H; Olmos, D; Adam, J; Plummer, ER; ... Judson, I; + view all (2009) A phase I study of AT9283, an aurora kinase inhibitor, in patients with refractory solid tumors. In: JOURNAL OF CLINICAL ONCOLOGY. (pp. ? - ?). AMER SOC CLINICAL ONCOLOGY

Kristeleit, R; O'Brien, M; (2009) Cardiotoxicity from cytotoxics in the 21st century. British Journal of Cardiology , 16 (2) 60 - 62.

Kulkarni, AA; Kingsbury, SR; Tudzarova, S; Hong, HK; Loddo, M; Rashid, M; ... Williams, GH; + view all (2009) Cdc7 Kinase Is a Predictor of Survival and a Novel Therapeutic Target in Epithelial Ovarian Carcinoma. CLIN CANCER RES , 15 (7) 2417 - 2425. 10.1158/1078-0432.CCR-08-1276.

L

Lajiness, J; Sielaff, A; MacKay, H; Brown, T; Kluza, J; Nguyen, B; ... Hartley, JA; + view all (2009) Polyamide Curvature and DNA Sequence Selective Recognition: Use of 4-Aminobenzamide to Adjust Curvature. MED CHEM , 5 (3) 216 - 226.

Lee, SM; Hackshaw, A; (2009) Correspondence. Response: Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomised, double-blind, placebo-controlled trial. Journal of the National Cancer Institute

Lee, SM; James, LE; Qian, W; Spiro, S; Eisen, T; Gower, NH; ... Rudd, RM; + view all (2009) Comparison of gemcitabine and carboplatin versus cisplatin and etoposide for patients with poor-prognosis small cell lung cancer. THORAX , 64 (1) 75 - 80. 10.1136/thx.2007.093872.

Lee, SM; Rudd, R; Woll, PJ; Ottensmeier, C; Gilligan, D; Price, A; ... Hackshaw, A; + view all (2009) Randomized double-blind placebo-controlled trial of thalidomide in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer. Journal of Clinical Oncology , 27 (31) 5248 - 5254.

Leitner, S; Sweeney, K; Oberg, D; Davies, D; Miranda, E; Lemoine, NR; Hallden, G; (2009) Oncolytic Adenoviral Mutants with E1B19K Gene Deletions Enhance Gemcitabine-induced Apoptosis in Pancreatic Carcinoma Cells and Anti-Tumor Efficacy In vivo. Clinical Cancer Research , 15 (5) 1730 - 1740. 10.1158/1078-0432.CCR-08-2008.

Liu, D; Zhang, T; Marshall, AJ; Okkenhaug, K; Vanhaesebroeck, B; Uzonna, JE; (2009) The p110delta isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cells. J Immunol , 183 (3) 1921 - 1933. 10.4049/jimmunol.0901099.

Loddo, M; Kingsbur, SR; Rashid, M; Proctor, I; Holt, C; Young, J; ... Williams, GH; + view all (2009) Cell cycle phase progression analysis identifies unique replication phenotypes of major prognostic and predictive significance in cancer. In: CANCER RESEARCH. (pp. 320S - 320S). AMER ASSOC CANCER RESEARCH

Loddo, M; Kingsbury, SR; Rashid, M; Proctor, I; Holt, C; Young, J; ... Williams, GH; + view all (2009) Cell-cycle-phase progression analysis identifies unique phenotypes of major prognostic and predictive significance in breast cancer. BRIT J CANCER , 100 (6) 959 - 970. 10.1038/sj.bjc.6604924.

Lolkema, MP; Harrington, K; Evans, J; Arkenau, HT; Roxburgh, P; Morrison, R; ... de Bono, J; + view all (2009) A phase-I study of the combination of intravenous reovirus (REOLYSIN (R)) and gemcitabine in patients with advanced cancer. In: EJC SUPPLEMENTS. (pp. 131 - 131).

M

Mahendran, AO; Elvey, M; Howie, AJ; Dupont, P; Veitch, PS; (2009) Early Renal Transplant Protocol Biopsies Directly Influence Patient Management. In: AMERICAN JOURNAL OF TRANSPLANTATION. (pp. 213 - 213). WILEY-BLACKWELL PUBLISHING, INC

Mahendran, AO; Elvey, M; Mahendran, M; Howie, AJ; Dupont, P; Veitch, PS; (2009) EARLY RENAL TRANSPLANT PROTOCOL BIOPSIES DIRECTLY INFLUENCE PATIENT MANAGEMENT. TRANSPL INT , 22 16 - 16.

Mahendran, AO; Haroon, S; Dupont, PJ; Howie, A; Veitch, PS; (2009) AN INCREMENTAL INCREASE IN CHRONIC ALLOGRAFT DAMAGE DETECTED ON PROTOCOL BIOPSIES DURING THE FIRST YEAR POST-TRANSPLANTATION. TRANSPL INT , 22 260 - 260.

Maniaci, V; Davidson, BR; Rolles, K; Dhillon, AP; Hackshaw, A; Begent, RH; Meyer, T; (2009) Fibrolamellar hepatocellular carcinoma - Prolonged survival with multimodality therapy. EJSO-EUR J SURG ONC , 35 (6) 617 - 621. 10.1016/j.ejso.2008.12.009.

McCabe, N; Cerone, MA; Ohishi, T; Seimiya, H; Lord, CJ; Ashworth, A; (2009) Targeting Tankyrase 1 as a therapeutic strategy for BRCA-associated cancer. Oncogene , 28 (11) 1465 - 1470. 10.1038/onc.2008.483.

McGovern, UB; Francis, RE; Peck, B; Guest, SK; Wang, J; Myatt, SS; ... Lam, EW; + view all (2009) Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther , 8 (3) 582 - 591. 10.1158/1535-7163.MCT-08-0805.

McGovern, UB; Stebbing, J; (2009) Receptor-based predictors of response in breast cancer. [Editorial comment]. Future Oncology , 5 (3) 283 - 286. 10.2217/fon.09.1. Green open access
file

Meyer, T; (2009) Interventional Radiological Treatment of Liver Tumours. British Journal of Cancer , 100 1975 - 1975.

Meyer, T; Gaya, AM; Dancey, G; Stratford, MRL; Othman, S; Sharma, SK; ... Begent, RH; + view all (2009) A Phase I Trial of Radioimmunotherapy with I-131-A5B7 Anti-CEA Antibody in Combination with Combretastatin-A4-Phosphate in Advanced Gastrointestinal Carcinomas. CLIN CANCER RES , 15 (13) 4484 - 4492. 10.1158/1078-0432.CCR-09-0035.

Michelagnoli, M; Kotecha, K; Anazado, A; Flanagan, A; Tirabosco, R; Briggs, T; ... Whelan, J; + view all (2009) OUTLOOK FOR CHILDREN UNDER 13 YEARS WITH PRIMARY MALIGNANT BONE TUMOURS - THE LONDON SARCOMA SERVICE EXPERIENCE 1999-2009. PEDIATR BLOOD CANCER , 53 (5) 797 - 798.

Mulder, K; Westrate, L; Brown, T; Mackay, H; Chavda, S; Babu, B; ... Lee, M; + view all (2009) DNA sequence selective recognition by the pyrrole(H)/N-methylpyrrole and pyrrole(H)/N-methylimidazole: Design, synthesis, and biophysical characteristics. ABSTR PAP AM CHEM S , 238 ? - ?.

Murugaesu, N; Powles, T; Bestwick, J; Oliver, RT; Shamash, J; (2009) Long-term follow-up of testicular cancer patients shows no predisposition to osteoporosis. Osteoporos Int , 20 (9) 1627 - 1630. 10.1007/s00198-008-0793-x.

O

Observer,; (2009) Smoking is a childhood addiction. Protect our children-vote to put tobacco out of sight.

Ogilvie, R; Plaunt, A; Riddering, C; Westrate, L; Davis, R; Ferguson, A; ... Lee, M; + view all (2009) ORGN 339-Design, synthesis and DNA binding properties of orthogonally positioned diamino-containing polyamides. ABSTR PAP AM CHEM S , 237 ? - ?.

Olmos, D; Arkenau, HT; Ang, JE; Ledaki, I; Attard, G; Carden, CP; ... de Bono, JS; + view all (2009) Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol , 20 (1) 27 - 33. 10.1093/annonc/mdn544.

P

Pacey, SC; Wilson, R; Walton, M; Eatock, M; Zetterlund, A; Arkenau, H; ... Judson, I; + view all (2009) A phase I trial of the HSP90 inhibitor, alvespimycin (17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumours. In: JOURNAL OF CLINICAL ONCOLOGY. (pp. ? - ?). AMER SOC CLINICAL ONCOLOGY

Panasyuk, G; Nemazanyy, I; Zhyvoloup, A; Filonenko, V; Davies, D; Robson, M; ... Gout, I; + view all (2009) mTOR beta Splicing Isoform Promotes Cell Proliferation and Tumorigenesis. J BIOL CHEM , 284 (45) 30807 - 30814. 10.1074/jbc.M109.056085. Gold open access

Pankhurst, T; Lepenies, J; Nightingale, P; Howie, AJ; Adu, D; Harper, L; (2009) Vasculitic IgA Nephropathy: Prognosis and Outcome. NEPHRON CLINICAL PRACTICE , 112 (1) C16 - C24. 10.1159/000210570.

Patkar, V; Acosta, D; Fox, J; Davidson, T; Keshtgar, M; Jones, A; (2009) A Novel Evidence-Adaptive Computerised Decision Support System for Breast Cancer Multidisciplinary Meetings: Results of an Evaluation Study. In: CANCER RESEARCH. (pp. 805S - 805S). AMER ASSOC CANCER RESEARCH

Paulussen, M; Craft, A; Lewis, I; Hackshaw, A; Douglas, C; Whelan, J; Jurgens, HFDEICESSSG; (2009) Zwei randomisierte Ewing Sarkom Studien Schweizer Krebsbulletin. Bulletin suisse du cancer , 29 (2) 128 - 134.

Pearce, S; Gibson, F; Eden, T; Glaser, A; Hooker, L; Whelan, J; Kelly, D; (2009) The experiences of young people from first symptoms to the diagnosis of cancer: a narrative study. In: European Journal of Cancer. (pp. 234 - ?).

Pearce, S; Gibson, F; Eden, TE; Glaser, A; Hooker, L; Whelan, J; Kelly, D; (2009) A narrative study of the experiences of young people from first symptoms to the diagnosis of cancer. In: National Cancer Research Institute Cancer Conference, 2009, Birmingham.

Plummer, R; Hayward, L; Lorigan, P; Soriano, V; Moiseyenko, V; Szyldergemajn, S; ... Calvert, H; + view all (2009) Plitidepsin alone or with dacarbazine (DTIC) as first-line treatment for advanced unresectable melanoma (AUM). In: JOURNAL OF CLINICAL ONCOLOGY. (pp. ? - ?). AMER SOC CLINICAL ONCOLOGY

Plummer, R; Vidal, L; Griffin, M; Lesley, M; de Bono, J; Coulthard, S; ... Bloody, AV; + view all (2009) Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors. CLIN CANCER RES , 15 (9) 3177 - 3183. 10.1158/1078-0432.CCR-08-2859.

Postel-Vinay, S; Arkenau, HT; Olmos, D; Ang, J; Barriuso, J; Ashley, S; ... Kaye, S; + view all (2009) Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? In: Br J Cancer. (pp. 1373 - 1378).

Q

Quinn, AE; Pinkney, M; Piggott, NH; Calvert, H; Milton, ID; Lunec, J; (2009) A Monoclonal Antibody for Detection of Folylpolyglutamate Synthetase in Paraffin Embedded Tissues. HYBRIDOMA , 28 (6) 415 - 421. 10.1089/hyb.2009.0040.

R

Razak, ARA; Nutt, JE; O'Toole, K; Black, F; Plummer, ER; Calvert, AH; Lunec, J; (2009) Expression of folate receptor alpha (FRa) in malignant pleural mesothelioma patients by immunohistochemistry: a clinico-pathological analysis. Lung Cancer , 63 82 - ?.

Rees, J; Short, S; Townsley, E; Zadeh, G; Brandner, S; Howard, R; ... Thomas, D; + view all (2009) Neuro-Oncology. In: UNSPECIFIED (771 - 822).

Ringland, CL; Arkenau, H-T; Ward, RL; O'Connell, DL; (2009) Second primary colorectal cancers (SPCRCs): Experiences from a large Australian cancer registry. Annals of Oncology , 21 (1) 92 - 97. 10.1093/annonc/mdp288.

S

Salma, Y; Lafont, E; Therville, N; Carpentier, S; Bonnafé, MJ; Levade, T; ... Andrieu-Abadie, N; + view all (2009) The natural marine anhydrophytosphingosine, Jaspine B, induces apoptosis in melanoma cells by interfering with ceramide metabolism. Biochem Pharmacol , 78 (5) 477 - 485. 10.1016/j.bcp.2009.05.002.

Short, SC; (2009) Re-irradiation of brain tumours-evidence, indications and limitations. In: Eur J Cancer. (pp. 410 - 411).

Spencer, J; Rathnam, RP; Motukuri, M; Kotha, AK; Richardson, SCW; Hazrati, A; ... Hursthouse, MB; + view all (2009) Synthesis of a 1,4-benzodiazepine containing palladacycle with in vitro anticancer and cathepsin B activity. DALTON T (22) 4299 - 4303. 10.1039/b819061e.

Srirajaskanthan, R; Dancey, G; Hackshaw, A; Luong, T; Caplin, ME; Meyer, T; (2009) Circulating angiopoietin-2 is elevated in patients with neuroendocrine tumours and correlates with disease burden and prognosis. ENDOCR-RELAT CANCER , 16 (3) 967 - 976. 10.1677/ERC-09-0089.

Srirajaskanthan, R; Desai, K; Jayaratnam, A; Carras, E; Toumpanakis, C; Meyer, T; Caplin, M; (2009) Uncommon sites for metastasis of neuroendocrine tumor in adults. In: JOURNAL OF CLINICAL ONCOLOGY.

Srirajaskanthan, R; McStay, M; Toumpanakis, C; Meyer, T; Caplin, ME; (2009) Parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumours: case series and literature review. Neuroendocrinology , 89 (1) 48 - 55. 10.1159/000151222.

Srirajaskanthan, R; Toumpanakis, C; Karpathakis, A; Marelli, L; Quigley, AM; Dusmet, M; ... Caplin, ME; + view all (2009) Surgical management and palliative treatment in bronchial neuroendocrine tumours: a clinical study of 45 patients. Lung Cancer , 65 (1) 68 - 73. 10.1016/j.lungcan.2008.10.025.

Srirajaskanthan, R; Toumpanakis, C; Meyer, T; Caplin, ME; (2009) Review article: future therapies for management of metastatic gastroenteropancreatic neuroendocrine tumours. Aliment Pharmacol Ther , 29 (11) 1143 - 1154. 10.1111/j.1365-2036.2009.03988.x.

Stephens, HA; Cox, S; Fernando, R; Howie, AJ; Harber, M; Little, A-M; (2009) MICA ANTIBODIES ASSOCIATE WITH BIOPSY-PROVEN CELLULAR REJECTION IN RENAL TRANSPLANT RECIPIENTS. TRANSPLANT INTERNATIONAL , 22 69 - 69.

Swanton, C; Nicke, B; Schuett, M; Eklund, AC; Ng, C; Li, Q; ... Downward, J; + view all (2009) Chromosomal instability determines taxane response. Proc Natl Acad Sci U S A , 106 (21) 8671 - 8676. 10.1073/pnas.0811835106.

T

Tan, DS; Brunetto, AT; Ang, J; Olmos, D; Barriuso, J; Frentzas, S; ... Kaye, SB; + view all (2009) Unplanned hospital admissions as an early surrogate indicator of patient (pt) attrition in phase I trials. In: JOURNAL OF CLINICAL ONCOLOGY. (pp. ? - ?). AMER SOC CLINICAL ONCOLOGY

Toumpanakis, C; Quigley, A; Srirajaskanthan, R; Marelli, L; Singhrao, T; Meyer, T; ... Caplin, ME; + view all (2009) 90-Yttrium-DOTA-octreotate for the treatment of advanced neuroendocrine tumors. In: JOURNAL OF CLINICAL ONCOLOGY.

U

UCL, SOLMSSN; (2009) Research Focus: Researchers conduct innovative targeted lung cancer trials. SLMS Newsletter September 2009 (5) 8 - 9.

V

Valle, JW; Wasan, H; Johnson, P; Jones, E; Dixon, L; Swindell, R; ... Bridgewater, J; + view all (2009) Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01. British Journal of Cancer , 101 (4) 621 - 627.

Valle, JW; Wasan, H; Johnson, P; Jones, E; Dixon, L; Swindell, R; ... Bridgewater, J; + view all (2009) Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study - The UK ABC-01 Study. BRIT J CANCER , 101 (4) 621 - 627. 10.1038/sj.bjc.6605211.

Van Cutsem, E; Rivera, F; Berry, S; Kretzschmar, A; Michael, M; DiBartolomeo, M; ... First BEAT investigators,; + view all (2009) Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT study. Ann Oncol , 20 (11) 1842 - 1847. 10.1093/annonc/mdp233.

Vassileva, V; (2009) Aberrant methylation - Early biomarker for CRC. Nature Reviews Clinical Oncology , 6 (12) 676 - 676. 10.1038/nrclinonc.2009.176.

Vassileva, V; (2009) Chemotherapy: Metastatic breast cancer—optimal front-line therapy. Nature Reviews Clinical Oncology , 6 (10) 557 - 557. 10.1038/nrclinonc.2009.135.

Vassileva, V; (2009) Chemotherapy: Predictors of chemotherapy response in advanced CRC. Nature Reviews Clinical Oncology , 6 (5) 245 - 245. 10.1038/nrclinonc.2009.31.

Vassileva, V; (2009) Diagnostic markers for ovarian cancer. Nature Reviews Clinical Oncology , 6 (12) 678 - 678. 10.1038/nrclinonc.2009.175.

Vassileva, V; (2009) Hematology: Early markers for leukemia. Nature Reviews Clinical Oncology , 6 (5) 245 - 245. 10.1038/nrclinonc.2009.34.

Vassileva, V; (2009) Imaging: FDG-PET/CT: early predictor of treatment response in soft-tissue sarcoma. Nature Reviews Clinical Oncology , 6 (7) 376 - 376. 10.1038/nrclinonc.2009.76.

Vassileva, V; (2009) Immunotherapy: Recurrence-free survival versus quality of life—where do we draw the line? Nature Reviews Clinical Oncology , 6 (9) 498 - 498. 10.1038/nrclinonc.2009.117.

Vassileva, V; (2009) Improved survival for SCRLM. Nature Reviews Clinical Oncology , 6 (9) 496 - 496. 10.1038/nrclinonc.2009.124.

Vassileva, V; (2009) MRI and molecular profiles: Improving prediction. Nature Reviews Clinical Oncology , 6 (8) 435 - 435. 10.1038/nrclinonc.2009.95.

Vassileva, V; (2009) Overdiagnosis with mammography? Nature Reviews Clinical Oncology , 6 (10) 556 - 556. 10.1038/nrclinonc.2009.138.

Vassileva, V; (2009) Pathology: Prostate cancer—personalized response prediction. Nature Reviews Clinical Oncology , 6 (11) 618 - 618. 10.1038/nrclinonc.2009.156.

Vassileva, V; (2009) Pathology: Protein kinase A predicts response to radiation and androgen deprivation therapy. Nature Reviews Clinical Oncology , 6 (11) 615 - 615. 10.1038/nrclinonc.2009.154.

Vassileva, V; (2009) Pediatric oncology: Aggressive treatment of osteosarcoma improves health-related quality of life. Nature Reviews Clinical Oncology , 6 (9) 498 - 498. 10.1038/nrclinonc.2009.123.

Vassileva, V; (2009) Prostate cancer: check it out. Nature Reviews Clinical Oncology , 6 (6) 303 - 303. 10.1038/nrclinonc.2009.53.

Vassileva, V; (2009) Surgery: Rectal cancer—treatment on the less invasive side. Nature Reviews Clinical Oncology , 6 (10) 557 - 557. 10.1038/nrclinonc.2009.136.

Vassileva, V; (2009) Surgical oncology: Markers of long-term survival in pancreatic cancer. Nature Reviews Clinical Oncology , 6 (7) 375 - 375. 10.1038/nrclinonc.2009.74.

Vassileva, V; (2009) Survivin: Surviving gastric cancer. Nature Reviews Clinical Oncology , 6 (8) 436 - 436. 10.1038/nrclinonc.2009.96.

Vassileva, V; (2009) Targeted therapies: Bevacizumab and chemotherapy in NSCLC. Nature Reviews Clinical Oncology , 6 (6) 304 - 304. 10.1038/nrclinonc.2009.54.

W

Westbury, CB; Reis-Filho, JS; Dexter, T; Mahler-Araujo, B; Fenwick, K; Iravani, M; ... Isacke, CM; + view all (2009) Genome-wide transcriptomic profiling of microdissected human breast tissue reveals differential expression of KIT (c-Kit, CD117) and oestrogen receptor-alpha (ER alpha) in response to therapeutic radiation. J PATHOL , 219 (1) 131 - 140. 10.1002/path.2581.

Westrate, L; Mackay, H; Brown, T; Nguyen, B; Kluza, J; Wilson, WD; ... Hartley, JA; + view all (2009) Effects of the N-Terminal Acylamido Group of Imidazole- and Pyrrole-Containing Polyamides on DNA Sequence Specificity and Binding Affinity. BIOCHEMISTRY-US , 48 (24) 5679 - 5688. 10.1021/bi900242t.

Wheatley-Price, P; Blackhall, F; Lee, SM; Ma, C; Ashcroft, L; Jitlal, M; ... Shepherd, FA; + view all (2009) The influence of sex and histology on outcomes in non-small cell lung cancer: a pooled analysis of 5 randomised trials. In: (Proceedings) Proffered Paper. 13th World Conference on Lung Cancer, San Franscisco, CA..

Whelan, J; (2009) Managing sarcomas in teenagers and young adults. In: EJC SUPPLEMENTS. (pp. 82 - 82). PERGAMON-ELSEVIER SCIENCE LTD

Whelan, JS; Patterson, D; Perisoglou, M; Bielack, S; Marina, N; Smeland, S; Bernstein, M; (2009) The role of interferons in the treatment of osteosarcoma. Pediatric Blood and Cancer 10.1002/pbc.22136.

Windsor, R; Strauss, S; Seddon, B; Michelagnoli, M; Labrum, R; Wood, N; ... J,; + view all (2009) A pilot pharmacogenomic study of the influence of cytotoxic target and metabolising gene polymorphisms on toxicity and response in osteosarcoma. In: European Musculoskeletal Oncology Society, Stuttgart, May 2009.

Windsor, R; Strauss, S; Seddon, B; Whelan, J; (2009) Experimental therapies in Ewing's sarcoma. EXPERT OPIN INV DRUG , 18 (2) 143 - 159. 10.1517/13543780802715784.

Windsor, R; Strauss, S; Seddon, B; Whelan, J; (2009) Experimental therapies in Ewing’s sarcoma. Expert Opin Investig Drugs , 18 , Article 2.

Y

Yong, M; Tolner, B; Nagl, S; Pedley, RB; Chester, K; Green, AJ; ... Begent, R; + view all (2009) Data standards for minimum information collection for antibody therapy experiments. PROTEIN ENG DES SEL , 22 (3) 221 - 224. 10.1093/protein/gzp003.

Yovine, A; Casali, P; G, RF; Vermorken, J; Demetri, G; Whelan, JS; ... Schoffski, P; + view all (2009) Trabectidin 3 hour infusion every 3 weeks in pre-treated advanced sarcoma patients: acompassionate use administration experience. In: European Journal of Cancer. (pp. 597 - ?).

This list was generated on Sun Oct 26 02:39:14 2014 GMT.